Interestingly, anti-IL-6 (Tocilizumab) improved intraocular inflammation in two ROSAH patients.12 This evidence concerns the gene IL6 and retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache syndrome.